SCHEMBL17617201

SCHEMBL17617201

CCCC[C@@](C)(CC)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
EPHX1 P07099 2/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
ATM Q13315 2/20 0.36
MEN1 O00255 1/20 0.36
DGAT1 O75907 1/20 0.35
ALDH1A1 P00352 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
PRSS1 P07477 1/20 0.33
CTSG P08311 1/20 0.33
CTRB1 P17538 1/20 0.33
CMA1 P23946 1/20 0.33
AR P10275 1/20 0.33
ZDHHC7 Q9NXF8 1/20 0.33
FDPS P14324 1/20 0.33
TSHR P16473 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9244382 1.00 CA1 (0.39) CA1CA2EPHX1L3MBTL1MAPT
SCHEMBL18030313 0.94 MAPT (0.42) CA1CA2EPHX1L3MBTL1MAPT
SCHEMBL19798107 0.92 MAPT (0.45) EPHX1L3MBTL1MAPTKMT2AATM
SCHEMBL7783336 0.92 MAPT (0.45) EPHX1L3MBTL1MAPTKMT2AATM
SCHEMBL28979874 0.92 MAPT (0.45) EPHX1L3MBTL1MAPTKMT2AATM
SCHEMBL5879071 0.92 MAPT (0.45) EPHX1L3MBTL1MAPTKMT2AATM
SCHEMBL5878909 0.92 MAPT (0.45) EPHX1L3MBTL1MAPTKMT2AATM
SCHEMBL27916266 0.91 CA1 (0.42) CA1CA2EPHX1L3MBTL1MAPT
SCHEMBL27916314 0.87 ALDH1A1 (0.39) CA1CA2EPHX1L3MBTL1MAPT
SCHEMBL20093567 0.87 MAPT (0.43) CA1CA2EPHX1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160083341-A1 METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE API CORPORATION (JP) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083341-A1 METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE MGMT, GSTA1, CBS CA1 683/4885CA2 929/4885EPHX1 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.